Barclays PLC Aquestive Therapeutics, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 99,312 shares of AQST stock, worth $350,571. This represents 0.0% of its overall portfolio holdings.
Number of Shares
99,312
Previous 99,312
-0.0%
Holding current value
$350,571
Previous $495,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding AQST
# of Institutions
122Shares Held
46.8MCall Options Held
517KPut Options Held
207K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$34.6 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY5.56MShares$19.6 Million2.87% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$19.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.26MShares$15.1 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.77MShares$9.77 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $188M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...